To fully harness precision medicine and transform cancer care for the better will require a strategic shift to highly personalized interventions that embrace innovation and adaptability.
Alzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry prot …
Abstract Here we describe the feasibility and first implementation of a mandatory, citywide premarital genomic screening program comprising the sequencing of 782 genes, implicated in autosomal recessi …
)
)